Advanced

Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations

Merseburger, Axel S.; Björk, Thomas LU ; Whitehouse, James and Meani, Davide (2015) In Journal of Comparative Effectiveness Research 4(5). p.447-453
Abstract
Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of Euro353,000 (EU5) and Euro699,000 (Sweden; 1-month... (More)
Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of Euro353,000 (EU5) and Euro699,000 (Sweden; 1-month formulations), and Euro259,000 (EU5) and Euro300,000 (Sweden; 3-month formulations). Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
costs, economics, leuprorelin, luteinizing hormone-releasing hormone, agonists, prostate cancer
in
Journal of Comparative Effectiveness Research
volume
4
issue
5
pages
447 - 453
publisher
Future Medicine Ltd.
external identifiers
  • wos:000363397600003
  • scopus:84945321592
ISSN
2042-6305
DOI
10.2217/cer.14.82
language
English
LU publication?
yes
id
41374421-0476-4e7a-85a1-5e8720ae1290 (old id 8201713)
date added to LUP
2015-12-01 07:07:28
date last changed
2017-10-22 04:26:22
@article{41374421-0476-4e7a-85a1-5e8720ae1290,
  abstract     = {Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of Euro353,000 (EU5) and Euro699,000 (Sweden; 1-month formulations), and Euro259,000 (EU5) and Euro300,000 (Sweden; 3-month formulations). Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations.},
  author       = {Merseburger, Axel S. and Björk, Thomas and Whitehouse, James and Meani, Davide},
  issn         = {2042-6305},
  keyword      = {costs,economics,leuprorelin,luteinizing hormone-releasing hormone,agonists,prostate cancer},
  language     = {eng},
  number       = {5},
  pages        = {447--453},
  publisher    = {Future Medicine Ltd.},
  series       = {Journal of Comparative Effectiveness Research},
  title        = {Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations},
  url          = {http://dx.doi.org/10.2217/cer.14.82},
  volume       = {4},
  year         = {2015},
}